Hims(US:HIMS) Youtube·2026-03-01 21:00Core Viewpoint - The latest quarterly results for Hims and Hers show mixed performance, with a notable focus on the impact of GLP1-related issues and a shift back to core business areas [2][4][5]. Financial Performance - Earnings per share (EPS) for the quarter were reported at 8 cents, which is double the street's expectations [2]. - Revenue for Q4 was approximately $617 million, slightly below the expected $619 million, with forward guidance for Q1 projected between $600 million to $625 million, lower than Wall Street's expectation of $654 million [3][4]. Business Strategy - Hims and Hers is pivoting away from a heavy reliance on GLP1 products, emphasizing growth in their sexual health and dermatology segments, which grew over 30% [5]. - The company has a subscriber base of 2.5 million, with only a small portion using GLP1s, indicating a broader business model beyond this product line [5]. Market Challenges - The company faces legal and regulatory challenges, particularly related to a lawsuit from Nova Nordisk, which may limit stock valuation in the near term [8]. - There is a noted decline in investor enthusiasm for Hims and Hers, primarily due to diminishing excitement around GLP1 products and pricing pressures [9]. Future Outlook - The addressable market for GLP1s is expected to grow, but Hims and Hers' lack of access to these products is seen as a significant disadvantage [10][12]. - The company is focusing on a personalized medicine strategy, which includes lab tests to tailor medications, indicating potential for growth despite current challenges [14].